TScan Therapeutics (TCRX) Competitors

TScan Therapeutics (NASDAQ:TCRX) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Do institutionals and insiders hold more shares of TCRX or ESPR?

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 4.4% of TScan Therapeutics shares are held by insiders. Comparatively, 1.7% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Do analysts prefer TCRX or ESPR?

TScan Therapeutics presently has a consensus price target of $7.80, suggesting a potential upside of 317.11%. Esperion Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 222.58%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Esperion Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Does the media prefer TCRX or ESPR?

In the previous week, TScan Therapeutics had 15 more articles in the media than Esperion Therapeutics. MarketBeat recorded 18 mentions for TScan Therapeutics and 3 mentions for Esperion Therapeutics. TScan Therapeutics' average media sentiment score of 0.29 beat Esperion Therapeutics' score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TScan Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Esperion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better valuation and earnings, TCRX or ESPR?

Esperion Therapeutics has higher revenue and earnings than TScan Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$2.82M	37.53	-$127.50M	-$1.09	-1.72
Esperion Therapeutics	$332.31M	1.32	-$51.74M	-$0.49	-4.43

Which has more risk and volatility, TCRX or ESPR?

TScan Therapeutics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Is TCRX or ESPR more profitable?

Esperion Therapeutics has a net margin of -35.84% compared to TScan Therapeutics' net margin of -1,964.88%. Esperion Therapeutics' return on equity of -0.91% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,964.88%	-63.33%	-40.19%
Esperion Therapeutics	-35.84%	-0.91%	-28.41%

Summary

TScan Therapeutics beats Esperion Therapeutics on 10 of the 16 factors compared between the two stocks.